Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.
A major challenge in the field of Gaucher disease has been the development of new therapeutic strategies including molecular chaperones. All previously described chaperones of glucocerebrosidase are enzyme inhibitors, which complicates their clinical development because their chaperone activity must be balanced against the functional inhibition of the enzyme. Using a novel high throughput screening methodology, we identified a chemical series that does not inhibit the enzyme but can still facilitate its translocation to the lysosome as measured by immunostaining of glucocerebrosidase in patient fibroblasts. These compounds provide the basis for the development of a novel approach toward small molecule treatment for patients with Gaucher disease.
NIH Chemical Genomic Center, National Center for Advancing Translation Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland, United States.
Samarjit
S
Patnaik
Wei
W
Zheng
Jae H
JH
Choi
Omid
O
Motabar
Noel
N
Southall
Wendy
W
Westbroek
Wendy A
WA
Lea
Arash
A
Velayati
Ehud
E
Goldin
Ellen
E
Sidransky
William
W
Leister
Juan J
JJ
Marugan
D000818:Animals; D018938:Caco-2 Cells; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D005776:Gaucher Disease / Q000188:drug therapy / Q000201:enzymology; D005962:Glucosylceramidase / Q000378:metabolism*; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010539:Permeability; D011743:Pyrimidines / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D054852:Small Molecule Libraries / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D011743:Pyrimidines; D054852:Small Molecule Libraries; D005962:Glucosylceramidase